New selective PAD4 inhibitors binding a calcium-deficient type of the PAD4 enzyme have validated the crucial enzymatic part of human and mouse PAD4 in both histone citrullination and neutrophil extracellular trap formation for, to our expertise, The very first time. The therapeutic opportunity of PAD4 inhibitors can now be explored. https://smedleyn776wju9.fare-blog.com/profile